Novo Nordisk Announces Semaglutide Price Reduct...

By João L. Carapinha

February 26, 2026

Novo Nordisk Drives Semaglutide Price Reduction Novo Nordisk slashes the US semaglutide list price—or wholesale acquisition cost (WAC)—for Wegovy®, Ozempic®, and Rybelsus® to $675 per ...
European Commission Approves Enhanced Wegovy Obesity Treatment Dose
South Africa Health Reform: Navigating Innovations and Challenges for 2026
Surge in Obesity Intervention Costs in the Netherlands
FDA Confirms GLP-1 RA Safety Review: No Increased Suicidal Risk
Obesity Medication Guidelines: Evidence-Based Approaches to Effective Treatment
Bausch Health’s Strategic Growth in Latin American Pharmaceuticals Thro...
WHO Guidelines Set New Standard for GLP-1 Obesity Therapies in Adults
Weight Loss: Advances in Hormone-Based Obesity Treatments
Eloralintide Obesity Treatment: Phase 2 Trial Reveals Significant Weight Loss...
Obesity Health Economics: Forecasting Trends and Costs in the US
Evolving Burden of Obesity in the US: Key Insights on Obesity Prevention Stra...
Insights on GLP-1 Therapy in Bariatric Surgery Patients